Literature DB >> 19895657

Osteoprotegerin concentrations and prognosis in acute ischaemic stroke.

J K Jensen1, T Ueland, D Atar, L Gullestad, H Mickley, P Aukrust, J L Januzzi.   

Abstract

AIM: Concentrations of osteoprotegerin (OPG) have been associated with the presence of vascular and cardiovascular diseases, but the knowledge of this marker in the setting of ischaemic stroke is limited. METHODS AND
RESULTS: In 244 patients with acute ischaemic stroke (age: 69 +/- 13 years), samples of OPG were obtained serially from presentation to day 5. Patients with overt ischaemic heart disease and atrial fibrillation were excluded. The patients were followed for 47 months, with all-cause mortality as the sole end-point. Multivariable predictors of OPG values at presentation included haemoglobin (T = -2.82; P = 0.005), creatinine (T = 4.56; P < 0.001), age (T = 9.66; P < 0.001), active smoking (T = 2.25; P = 0.025) and pulse rate (T = 3.23; P = 0.001). At follow-up 72 patients (29%) had died. Patients with OPG < or =2945 pg mL(-1) at baseline had a significantly improved survival rate on univariate analysis (P < 0.0001); other time-points did not add further prognostic information. In multivariate analysis, after adjustment for age, stroke severity, C-reactive protein levels, troponin T levels, heart and renal failure concentrations of OPG independently predicted long-term mortality after stroke (adjusted hazard ratio, 2.3; 95% CI: 1.1 to 4.9; P = 0.024).
CONCLUSION: Osteoprotegerin concentrations measured at admission of acute ischaemic stroke are associated with long-term mortality.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19895657     DOI: 10.1111/j.1365-2796.2009.02163.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  12 in total

1.  OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice.

Authors:  Munehisa Shimamura; Hironori Nakagami; Mariana K Osako; Hitomi Kurinami; Hiroshi Koriyama; Pang Zhengda; Hideki Tomioka; Akiko Tenma; Kouji Wakayama; Ryuichi Morishita
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-20       Impact factor: 11.205

Review 2.  The role of the RANKL/RANK/OPG system in the central nervous systems (CNS).

Authors:  Reiko Hanada
Journal:  J Bone Miner Metab       Date:  2020-09-04       Impact factor: 2.626

3.  Significant Association between OPG/TNFRSF11B Variant and Common Complex Ischemic Stroke.

Authors:  Xin Xiong; Duraid Hamied Naji; Binbin Wang; Yuanyuan Zhao; Junhan Wang; Dan Wang; Yuting Zhang; Sisi Li; Shanshan Chen; Yufeng Huang; Qin Yang; Xiaojing Wang; Dan Yin; Xin Tu; Qiuyun Chen; Xu Ma; Chengqi Xu; Qing K Wang
Journal:  J Stroke Cerebrovasc Dis       Date:  2018-02-28       Impact factor: 2.136

4.  Osteoprotegerin levels in patients with severe mental disorders.

Authors:  Sigrun Hope; Ingrid Melle; Pål Aukrust; Ingrid Agartz; Steinar Lorentzen; Nils Eiel Steen; Srdjan Djurovic; Thor Ueland; Ole A Andreassen
Journal:  J Psychiatry Neurosci       Date:  2010-09       Impact factor: 6.186

5.  Association between TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients.

Authors:  Federico Biscetti; Giuseppe Straface; Silvia Giovannini; Angelo Santoliquido; Flavia Angelini; Luca Santoro; Carlo Filippo Porreca; Giovanni Pecorini; Giovanni Ghirlanda; Andrea Flex
Journal:  Hum Genet       Date:  2012-09-11       Impact factor: 4.132

6.  Immediately transcripted genes in various hepatic ischemia models.

Authors:  Kang Kook Choi; Jin A Cho; Se Hoon Kim; Sang Woo Lee; Seon Ok Min; Kyung Sik Kim
Journal:  J Korean Surg Soc       Date:  2012-10-29

7.  Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes.

Authors:  Ragnhild Røysland; Marc P Bonaca; Torbjørn Omland; Marc Sabatine; Sabina A Murphy; Benjamin M Scirica; Mette Bjerre; Allan Flyvbjerg; Eugene Braunwald; David A Morrow
Journal:  Heart       Date:  2012-02-28       Impact factor: 5.994

8.  Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging.

Authors:  E Kastritis; M Gavriatopoulou; M A Dimopoulos; E Eleutherakis-Papaiakovou; N Kanellias; M Roussou; C Pamboucas; S T Toumanidis; E Terpos
Journal:  Blood Cancer J       Date:  2015-06-05       Impact factor: 11.037

9.  Osteoprotegerin as a marker of atherosclerosis in diabetic patients.

Authors:  Areti Augoulea; Nikolaos Vrachnis; Irene Lambrinoudaki; Konstantinos Dafopoulos; Zoe Iliodromiti; Angelos Daniilidis; Michail Varras; Andreas Alexandrou; Efthymios Deligeoroglou; George Creatsas
Journal:  Int J Endocrinol       Date:  2013-01-17       Impact factor: 3.257

Review 10.  Osteoprotegerin rich tumor microenvironment: implications in breast cancer.

Authors:  Sudeshna Goswami; Neelam Sharma-Walia
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.